All Oncology News

The Hamilton of Medicine

September 3rd 2021

Most physician-scientists are intense, motivated and focused, but Keith T. Flaherty, MD, takes it to another level.

Genomic-Adjusted Radiation Dose Is Associated With First Recurrence and Survival in Solid Tumors

September 3rd 2021

Genomic-adjusted radiation dose demonstrated a significant association with time to first recurrence and overall survival in patients with certain solid tumors who had been treated with radiation therapy, indicating that genomics should be used to guide radiation dosing decisions.

New SITC Guidelines Provide First Recommendations for Immunotherapy in TNBC

September 2nd 2021

Following the integration of immunotherapy into the treatment paradigm of triple-negative breast cancer, a multidisciplinary panel of experts, brought together by the Society for Immunotherapy of Cancer, published the first clinical practice guidelines focused on navigating clinical decisions with immunotherapy in breast cancer.

Neoadjuvant Cabozantinib/Nivolumab Leads to Improved Resection Rates in HCC

September 2nd 2021

The combination of cabozantinib and nivolumab as a neoadjuvant regimen led to encouraging margin-negative resection and major pathological response rates in patients with hepatocellular carcinoma, according to results of a single-arm, phase 1b study that were published in Nature Cancer.

UV1 Vaccine Plus Pembrolizumab Shows Strong Safety, Early Activity in Metastatic Melanoma

September 2nd 2021

The universal cancer vaccine UV1 and granulocyte-macrophage colony-stimulating factor in combination with pembrolizumab elicited encouraging initial signs of clinical response with favorable safety and tolerability when used in the first-line treatment of patients with metastatic melanoma, meeting the primary end point of an ongoing phase 1 trial.

FDA Grants Orphan Drug Status to Gavocabtagene Autoleucel for Cholangiocarcinoma

September 2nd 2021

The FDA has granted an orphan drug designation to gavocabtagene autoleucel as a potential treatment for patients with cholangiocarcinoma.

Untangling Fact From Bias in the Age of Social Media and Mistrust

September 2nd 2021

It is difficult to overstate the confusion associated with our nation’s messaging regarding a well-considered, rational, and scientifically based public health–focused approach to the current and future ramifications of the COVID-19 pandemic.

Pevonedistat/Azacitidine Misses EFS End Point in Frontline Higher-Risk MDS/CMML, Low-Blast AML

September 2nd 2021

The combination of pevonedistat plus azacitidine as a frontline treatment for patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and low-blast acute myeloid leukemia did not achieve predefined statistical significance for the primary end point of event-free survival in the phase 3 PANTHER trial.

Gymnastics Makes Me a Better Oncologist

September 2nd 2021

Valentina Baez Sosa, MD, shares how her early life experiences in gymnastics and coaching have helped her become a better hematology/oncology physician.

PACIFIC Led to Subtle but Swift Adoption of Concurrent Chemoradiation and Durvalumab in Stage III NSCLC

September 2nd 2021

An increase in the use of concurrent chemoradiation followed by durvalumab was found in patients with stage III non–small cell lung cancer who were treated at 3 Dutch centers in The Netherlands between 2015 and 2019.

FDA Approves Zanubrutinib in Waldenström Macroglobulinemia

September 1st 2021

The FDA has approved zanubrutinib for the treatment of adult patients with Waldenström macroglobulinemia.

Rolling Submission of BLA to FDA Completed for Toripalimab Plus Chemotherapy in Metastatic Nasopharyngeal Carcinoma

September 1st 2021

The rolling submission of a biologics license application to support the approval of both toripalimab plus gemcitabine- and cisplatin-based chemotherapy as a first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma, as well as toripalimab monotherapy for the second-line or beyond treatment of patients with recurrent or metastatic nasopharyngeal carcinoma after platinum-based chemotherapy has been completed.

Emerging Options Open the Door to Optimized Treatment Opportunities in Hematologic Malignancies

September 1st 2021

More tailored selection processes, which have placed a greater emphasis on patient-specific characteristics, such as risk and genomic status, and made possible with a growing number of treatment options, have led to optimized therapeutic decisions for patients with hematologic malignancies.

Topical Remetinostat Demonstrates Efficacy, Tolerability in Basal Cell Carcinoma

September 1st 2021

The topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial.

Biomarker Discovery and Testing Are Key to Improving Care for Early-Stage Resectable NSCLC

September 1st 2021

Jay M. Lee, MD, discusses the implications of the ADAURA trial in early-stage resectable NSCLC, the importance of molecular testing, and the need for a multidisciplinary approach in this population.

Zanidatamab Plus Tucatinib/Capecitabine Is Being Tested in Advanced HER2+ Breast Cancer

September 1st 2021

Zanidatamab is being combined with tucatinib and capecitabine in a new cohort of a phase 1 trial of patients with locally advanced and/or metastatic HER2-positive breast cancer.

Paving the Way to Modern Cancer Therapy

September 1st 2021

When George P. Canellos, MD, first joined the field of oncology in the 1960s, many of his peers thought he was making huge mistake.

Neo–Epitope-Based Vaccine Plus Pembrolizumab Under Exploration in Ovarian Cancer

September 1st 2021

The neo–epitope-based vaccine Tedopi is under investigation either alone or in combination with pembrolizumab as maintenance treatment vs best supportive care in patients with recurrent ovarian cancer following platinum-based chemotherapy as part of the phase 2 TEDOVA trial.

P-PSMA-101 Elicits Encouraging Responses in Metastatic Castration-Resistant Prostate Cancer

September 1st 2021

The autologous CAR T-cell therapy P-PSMA-101 elicited robust antitumor responses in patients with metastatic castration-resistant prostate cancer, according to preliminary findings from the phase 1 P-PSMA-101-001 trial that were virtually presented during the 6th Annual CAR-TCR Summit.

FDA Grants Full Approval to Pembrolizumab for Select Locally Advanced or Metastatic Urothelial Cancer

August 31st 2021

The FDA has granted a full approval to pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy.